6:48 PM
 | 
Sep 10, 2009
 |  BC Extra  |  Company News

Amylin, Biocon in diabetes deal

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) and Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) partnered to jointly develop and commercialize a peptide therapeutic based...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >